Related Experiment Video
Updated: Jan 30, 2026

Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying
Mariana Castanheira1, Andrew P Davis1, Alisa W Serio2
1JMI Laboratories, North Liberty, IA 52317.
Abstract:
Aminoglycoside-nonsusceptible isolates of Escherichia coli, Klebsiella, Proteus, and Enterobacter species (480/3675) from US hospitals collected during 2014-2015 were screened for 16S rRNA methyltransferase and aminoglycoside-modifying enzyme (AME) genes. Only 5 isolates had high aminoglycoside MICs and carried 16S rRNA methyltransferases. AME genes were observed among 89.7% (426/475) of isolates and the most common genes were aac(3)-IIa (n = 270) and aac(6')-Ib (n = 269). Among other genes, ant(2″)-Ia, aac(3)-Iva, and aph(3')-VIa were observed among 36, 23, and 3 isolates, respectively. Forty-nine (10.3%) isolates yielded negative results for the investigated AME genes. Plazomicin (MIC50/90, 0.5/1 μg/ml) inhibited 99.3% of the AME-carrying isolates at its susceptible breakpoint while amikacin, gentamicin, and tobramycin inhibited 90.1%, 20.9%, and 18.3%, respectively. Plazomicin was approved by the US Food and Drug Administration in June 2018 for the treatment of complicated urinary tract infections when limited treatment options are available. This agent displayed activity against isolates carrying AMEs that were resistance to other aminoglycosides and comparator agents.
Insights
Aminoglycoside-modifying enzyme (AME) genes are common in resistant Gram-negative bacteria. Plazomicin effectively inhibits AME-carrying isolates, offering a vital option for difficult-to-treat infections.
Area of Science:
- Microbiology
- Antimicrobial Resistance
- Infectious Diseases
Background:
- Aminoglycoside resistance is a growing threat in Gram-negative bacterial infections.
- Aminoglycoside-modifying enzymes (AMEs) are a primary mechanism of resistance.
- Limited treatment options exist for infections caused by aminoglycoside-resistant bacteria.
Purpose of the Study:
- To screen aminoglycoside-nonsusceptible Gram-negative isolates for AME and 16S rRNA methyltransferase genes.
- To evaluate the in vitro activity of plazomicin against these resistant isolates.
- To compare plazomicin's efficacy with other aminoglycosides.
Main Methods:
- Screening of 480 Gram-negative isolates from US hospitals (2014-2015) for resistance genes.
- Detection of 16S rRNA methyltransferase and AME genes using molecular methods.
- Antimicrobial susceptibility testing, including minimum inhibitory concentrations (MICs) for plazomicin and comparators.
Main Results:
- AME genes were found in 89.7% of isolates; common genes included aac(3)-IIa and aac(6')-Ib.
- Only 5 isolates carried 16S rRNA methyltransferases.
- Plazomicin demonstrated potent activity (MIC50/90, 0.5/1 μg/ml), inhibiting 99.3% of AME-carrying isolates, significantly outperforming amikacin, gentamicin, and tobramycin.
Conclusions:
- AME genes are prevalent in aminoglycoside-nonsusceptible Gram-negative bacteria.
- Plazomicin exhibits significant in vitro activity against a broad range of AME-producing Gram-negative pathogens.
- Plazomicin represents a valuable therapeutic option for complicated urinary tract infections with limited treatment choices.
Related Concept Videos
Estimation of k and VD of Aminoglycosides
Enzymes and Activation Energy
Enzymes
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
tRNA Activation
Common Ion Effect
Genome Size and the Evolution of New Genes

